» Articles » PMID: 32677879

Synthetic Repurposing of Drugs Against Hypertension: a Datamining Method Based on Association Rules and a Novel Discrete Algorithm

Overview
Publisher Biomed Central
Specialty Biology
Date 2020 Jul 18
PMID 32677879
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Drug repurposing aims to detect the new therapeutic benefits of the existing drugs and reduce the spent time and cost of the drug development projects. The synthetic repurposing of drugs may prove to be more useful than the single repurposing in terms of reducing toxicity and enhancing efficacy. However, the researchers have not given it serious consideration. To address the issue, a novel datamining method is introduced and applied to repositioning of drugs for hypertension (HT) which is a serious medical condition and needs some improved treatment plans to help treat it.

Results: A novel two-step data mining method, which is based on the If-Then association rules as well as a novel discrete optimization algorithm, was introduced and applied to the synthetic repurposing of drugs for HT. The required data were also extracted from DrugBank, KEGG, and DrugR+ databases. The findings indicated that based on the different statistical criteria, the proposed method outperformed the other state-of-the-art approaches. In contrast to the previously proposed methods which had failed to discover a list on some datasets, our method could find a combination list for all of them.

Conclusion: Since the proposed synthetic method uses medications in small dosages, it might revive some failed drug development projects and put forward a suitable plan for treating different diseases such as COVID-19 and HT. It is also worth noting that applying efficient computational methods helps to produce better results.

Citing Articles

Advancement of Computational Design Drug Delivery System in COVID-19: Current Updates and Future Crosstalk- A Critical update.

Mohiuddin A, Mondal S Infect Disord Drug Targets. 2023; .

PMID: 37584349 PMC: 11348471. DOI: 10.2174/1871526523666230816151614.


A voting-based machine learning approach for classifying biological and clinical datasets.

Daneshvar N, Masoudi-Sobhanzadeh Y, Omidi Y BMC Bioinformatics. 2023; 24(1):140.

PMID: 37041456 PMC: 10088226. DOI: 10.1186/s12859-023-05274-4.


A fuzzy logic-based computational method for the repurposing of drugs against COVID-19.

Masoudi-Sobhanzadeh Y, Esmaeili H, Masoudi-Nejad A Bioimpacts. 2022; 12(4):315-324.

PMID: 35975205 PMC: 9376160. DOI: 10.34172/bi.2021.40.


Structure-based drug repurposing against COVID-19 and emerging infectious diseases: methods, resources and discoveries.

Masoudi-Sobhanzadeh Y, Salemi A, Pourseif M, Jafari B, Omidi Y, Masoudi-Nejad A Brief Bioinform. 2021; 22(6).

PMID: 33993214 PMC: 8194848. DOI: 10.1093/bib/bbab113.


World competitive contest-based artificial neural network: A new class-specific method for classification of clinical and biological datasets.

Arabi Bulaghi Z, Navin A, Hosseinzadeh M, Rezaee A Genomics. 2020; 113(1 Pt 2):541-552.

PMID: 32991962 PMC: 7521912. DOI: 10.1016/j.ygeno.2020.09.047.

References
1.
Masoudi-Sobhanzadeh Y, Omidi Y, Amanlou M, Masoudi-Nejad A . DrugR+: A comprehensive relational database for drug repurposing, combination therapy, and replacement therapy. Comput Biol Med. 2019; 109:254-262. DOI: 10.1016/j.compbiomed.2019.05.006. View

2.
Sridhar D, Fakhraei S, Getoor L . A probabilistic approach for collective similarity-based drug-drug interaction prediction. Bioinformatics. 2016; 32(20):3175-3182. DOI: 10.1093/bioinformatics/btw342. View

3.
Frishman W . Beta-Adrenergic Receptor Blockers in Hypertension: Alive and Well. Prog Cardiovasc Dis. 2016; 59(3):247-252. DOI: 10.1016/j.pcad.2016.10.005. View

4.
Johnson R, Bakris G, Borghi C, Chonchol M, Feldman D, Lanaspa M . Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation. Am J Kidney Dis. 2018; 71(6):851-865. PMC: 7286363. DOI: 10.1053/j.ajkd.2017.12.009. View

5.
Alencar A, Carvalho F, Silva A, Martinez S, Calasans-Maia J, Fraga C . Synergistic interaction between a PDE5 inhibitor (sildenafil) and a new adenosine A2A receptor agonist (LASSBio-1359) improves pulmonary hypertension in rats. PLoS One. 2018; 13(4):e0195047. PMC: 5909907. DOI: 10.1371/journal.pone.0195047. View